Vol 8, No 2 (2017)
Research paper
Published online: 2017-09-06

open access

Page views 2117
Article views/downloads 3808
Get Citation

Connect on Social Media

Connect on Social Media

Incidence and disease prevalence for hematologic neoplasms in Poland (2009–2015) as determined on the analysis of the National Health Fund data used in the project ‘Maps of healthcare needs — database of systemic and implementation analyses’

Bożena Katarzyna Budziszewska12, Barbara Więckowska34, Ewa Lech-Marańda12, Tomasz Mikołajczyk3, Janusz Dagiel3, Wiesław Wiktor Jędrzejczak5
Hematologia 2017;8(2):89-104.


In Poland, there is a shortage of statistical data regarding neoplasia of hematopoietic system. There is an unmet demand for epidemiological data concerning such cancers stemming from both scientific and health care management reasons. As all medical services for patients with these disorders are reported to the National Health Fund (NFZ) the aim of this study was to use NFZ data for determining incidence and prevalence of neoplasia of myelopoietic part of hematopoietic system in Poland, as well as defining the overall survival (OS) in affected patients. This work was performed under the project ‘Map of healthcare needs — database of systemic and implementation analyses’ co-funded by the European Union Social Fund from the Operational Programme for the Development of Knowledge and Education. The incidence rate in 2014 for acute myeloid leukaemia (AML) was 4.1/100,000 whilst the registered disease prevalence rate was 10.9/100,000. The median OS during 2009–2015 for AML — reported patients was 6 months and the 3- and 5-year OS was estimated as respectively being 26.5% and 23.4%. For chronic myelogenous leukemia (CML) the incidence and disease prevalence rates were 1.0/100,000 and 7.2/100,000 respectively, and those for Philadelphia-negative myeloproliferative neoplasms (MPN Ph–) were 8.9/100,000 and 55.9/100,000 respectively, whilst those for myelodysplastic syndromes (MDS) were 3.8/100,000 and 11.5/100,000 respectively. In patients reported as having CML, the 3- and 5-year OS was 76.2% and 68.1% respectively. In patients reported as having MPN Ph(–), the 3- and 5-year OS was 86.6% and 78.6% respectively. The median OS for patients reported as having MDS was 30 months and the probability of patients achieving 3- and 5-year OS was 45.8% and 36.1% respectively. Data reported to the NFZ for reimbursement of medical services provided seem to be the most reliable concerning such large patient population. Yet, there are still prone to errors arising from the mis-coding of cancers and to limited compatibility of the ICD-10th Revision (International Classification of Diseases) to current World Health Organization classification, Nevertheless, our data are similar to the European and USA registers regarding AML and MDS. However, in the case of MPNs (CML excluding) they require further verification.


  1. Więckowska B, Koń B, Dagiel J. et al. Choroby onkologiczne w Polsce — wyniki modelu prognostycznego na lata 2015–2025. In: Więckowska B. ed. Onkologia. Vol. 1. Proces leczenia w Polsce — analizy i modele. Ministerstwo Zdrowia, Warszawa 2015: 292.
  2. http://www.mapypotrzebzdrowotnych.mz.gov.pl/mapy-dla-30-grup-chorob/ (30.06.2017).
  3. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2016. https://www.R-project.org/ (30.06.2017).
  4. RStudio Team. RStudio: integrated development for R. RStudio Inc., Boston. http://www.rstudio.com/ (30.06.2017).
  5. Dowle M, Srinivasan A. data.table: Extension of 'data.frame'. R package version 1.10.4. https://CRAN.R-project.org/package=data.table (30.06.2017).
  6. Wickham H. ggplot2: elegant graphics for data analysis. Springer-Verlag, New York 2016. http://ggplot2.org (30.06.2017).
  7. Therneau T. A package for survival analysis in S. version 2.38. 2015. http://CRAN.R-project.org/package=survival (30.06.2017).
  8. Therneau T, Grambsch PM. Modeling survival data: extending the Cox model. Springer, New York 2000.
  9. https://seer.cancer.gov/ (30.06.2017).
  10. Sant M, Allemani C, Tereanu C, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116(19): 3724–3734.
  11. Seferyńska I, Warzocha K. Raport z rejestru zachorowań na ostre białaczki u osób dorosłych w Polsce w latach 2004–2010 prowadzonego przez Instytut Hematologii i Transfuzjologii w imieniu Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG). Hematologia. 2014; 5: 162–172.
  12. Juliusson G, Lazarevic V, Hörstedt AS, et al. Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119(17): 3890–3899.
  13. Gangatharan SA, Grove CS, P'ng S, et al. Acute myeloid leukaemia in Western Australia 1991–2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. Intern Med J. 2013; 43(8): 903–911.
  14. Bhayat F, Das-Gupta E, Smith C, et al. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009; 9: 252.
  15. Maynadié M, De Angelis R, Marcos-Gragera R, et al. HAEMACARE Working Group. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013; 98(2): 230–238.
  16. Thein MS, Ershler W, Jemal A, et al. Outcome of older patients with acute myeloid leukemia. Cancer. 2013; 119(15): 2720–2727.
  17. Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015; 94(7): 1127–1138.
  18. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014; 92(4): 289–297.
  19. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016; 174(3): 382–396.
  20. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.
  21. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014; 89(6): 581–587.
  22. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014; 55(3): 595–600.
  23. Roman E, Smith A, Appleton S, et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004–15. Cancer Epidemiol. 2016; 42: 186–198.
  24. Cartwright R, Ricketts T. Leukaemias and lymphoma: an atlas of distribution within areas of England and Wales 1984–88. Leukaemia Research Fundation, London 1990.
  25. Aul C, Gattermann N, Schneider W, et al. [Myelodysplastic syndromes. The epidemiological and etiological aspects]. Dtsch Med Wochenschr. 1992; 117(33): 1223–1231.
  26. Rådlund A, Thiede T, Hansen S, et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995; 54(3): 153–156.
  27. Maynadié M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996; 74(2): 288–290.
  28. Drozd-Sokołowska JE, Mądry K, Waszczuk-Gajda A, et al. Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. Eur J Haematol. 2017; 98(2): 154–159.

Hematology in Clinical Practice